Merck & Co. Files 3Q24 10-Q Report
Ticker: MRK · Form: 10-Q · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Merck's 3Q24 10-Q is in: check financials for Q3 performance.
AI Summary
Merck & Co., Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position for the third quarter of 2024. Key financial data and disclosures relevant to investors are presented in this report.
Why It Matters
This 10-Q filing provides crucial financial updates for Merck & Co., Inc., allowing investors to assess the company's performance and make informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing (10-Q) and does not inherently present new risks.
Key Players & Entities
- Merck & Co., Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241106 (date) — Filing date
- 0000310158 (company) — Central Index Key for Merck & Co., Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on November 6, 2024.
What is Merck & Co., Inc.'s Central Index Key (CIK)?
Merck & Co., Inc.'s Central Index Key is 0000310158.
What is Merck's fiscal year end?
Merck's fiscal year ends on December 31.
What is the business address of Merck & Co., Inc.?
The business address is 2000 Galloping Hill Road, Kenilworth, NJ 07033.
From the Filing
0001628280-24-045689.txt : 20241106 0001628280-24-045689.hdr.sgml : 20241106 20241106160536 ACCESSION NUMBER: 0001628280-24-045689 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 98 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 241430881 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20240930.htm 3Q24 FORM 10-Q mrk-20240930 FALSE 2024 Q3 0000310158 12/31 http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense xbrli:shares iso4217:USD iso4217:USD xbrli:shares mrk:aqua_facility xbrli:pure mrk:candidate mrk:jurisdiction mrk:interest_rate_swap iso4217:EUR mrk:case mrk:employee mrk:motion mrk:lawsuit mrk:company mrk:patent mrk:segment 0000310158 2024-01-01 2024-09-30 0000310158 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000310158 mrk:A1.875Notesdue2026Member 2024-01-01 2024-09-30 0000310158 mrk:A3.250NotesDue2032Member 2024-01-01 2024-09-30 0000310158 mrk:A2.500Notesdue2034Member 2024-01-01 2024-09-30 0000310158 mrk:A1.375Notesdue2036Member 2024-01-01 2024-09-30 0000310158 mrk:A3.500NotesDue2037Member 2024-01-01 2024-09-30 0000310158 mrk:A3.700NotesDue2044Member 2024-01-01 2024-09-30 0000310158 mrk:A3.750NotesDue2054Member 2024-01-01 2024-09-30 0000310158 2024-10-31 0000310158 2024-07-01 2024-09-30 0000310158 2023-07-01 2023-09-30 0000310158 2023-01-01 2023-09-30 0000310158 2024-09-30 0000310158 2023-12-31 0000310158 2022-12-31 0000310158 2023-09-30 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-09-01 2024-09-30 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-09-30 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-07-01 2024-09-30 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-01-01 2024-09-30 0000310158 mrk:ThirdPartyMember mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-09-30 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember 2024-07-01 2024-07-31 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember 2024-07-09 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember mrk:OtherProductRightsMember 2024-07-09 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember mrk:ProductRightsMember 2024-07-09 0000310158 mrk:EyebiotechLimitedMember 2024-07-01 2024-07-31 0000310158 mrk:EyebiotechLimitedMember 2024-07-31 0000310158 mrk:EyebiotechLimitedMember 2024-07-01 2024-09-30 0000310158 mrk:EyebiotechLimitedMember 2024-01-01 2024-09-3